Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting
April 27 2022 - 10:01AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing therapeutics that combine both targeted
and immune-mediated mechanisms, today announced that two abstracts
were accepted for presentation at the 2022 American Society of
Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022
at the McCormick Place Convention Center in Chicago, IL. The
results of the Phase 1 monotherapy and Phase 1 combination therapy
studies with TPST-1120, a potential first-in-class PPARα
antagonist, received an invitation for an oral presentation. The
trial results will be presented on the podium by Mark Yarchoan, a
clinical investigator from Johns Hopkins School of Medicine.
In addition, the trials-in-progress abstract for
TPST-1495, a potential first-in-class EP2/EP4 prostaglandin
receptor dual antagonist, was accepted for a poster
presentation.
“We are thrilled that ASCO recognized our two
novel clinical programs and accepted the abstracts for
presentation,” commented Stephen Brady, chief executive officer of
Tempest. “This will be the first presentation of clinical data from
a Tempest program, and we are encouraged by the results from our
completed Phase 1 study with TPST-1120, and excited about the
ongoing first-line randomized study in patients with hepatocellular
carcinoma.”
Our abstracts will be released on Thursday, May
26, 2022 at 5:00 p.m. EDT on ASCO.org/abstracts. We expect to also
include data from the additional TPST-1120 patients enrolled after
abstract submission.
Presentation details:
Title: A phase 1 study of
TPST-1120 as a single agent and in combination with nivolumab in
subjects with advanced solid tumors.
Session Typer/Title: Oral
Abstract Session, Developmental Therapeutics – Molecularly Targeted
Agents and Tumor BiologySession Date and Time:
Tuesday, June 7, 2022; 9:45 a.m. - 12:45 p.m. CDTAbstract
Number: 3005
Title: A phase 1 study of
TPST-1495 as a single agent and in combination with pembrolizumab
in subjects with solid tumors
Session Type/Title:
Poster Session, Developmental Therapeutics – Immunotherapy
Session Date and Time: Sunday, June 5, 2022; 8:00
a.m. – 11:00 a.m. CDT Abstract Number:
TPST2696
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company’s two novel clinical
programs are TPST-1120 and TPST-1495, antagonists of PPARα and
EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing
through Phase 1 clinical trials designed to study both agents as
monotherapies and in combination with other approved agents. In
collaboration with F. Hoffmann La Roche, TPST-1120 is also
advancing through a randomized first line, global, Phase 1b/2
clinical study in combination with the standard-of-care regimen of
atezolizumab and bevacizumab in patients with advanced or
metastatic hepatocellular carcinoma. Tempest is also developing an
orally-available inhibitor of TREX-1 designed to activate
selectively the cGAS/STING pathway, an innate immune response
pathway important for the development of anti-tumor immunity.
Tempest is headquartered in South San Francisco. More information
about Tempest can be found on the company’s website at
www.tempesttx.com.
Investor Contact:
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Media Contact:
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@tempesttx.com
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Oct 2023 to Oct 2024